{"transactions":[{"id":1049203,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2025-09-03T17:00:21.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":96000,"price":0.0099,"value":950.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose sale is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-087085","document":"tm2525128d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465925087085/tm2525128d1_4seq1.xml","form_type":"4"}},{"id":1052726,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2025-08-29T22:25:42.000Z","date":"2025-08-28","kind":"sale","planned":false,"acquired":false,"shares":207000,"price":0.0101,"value":2090.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose sale is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer."}],"balance_after":986352,"source":{"system":"sec-edgar","filing":"0001104659-25-085820","document":"tm2524763-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925085820/tm2524763-1_4seq1.xml","form_type":"4"}},{"id":1061205,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of 0.001 GBP per share","published_at":"2025-08-19T23:07:09.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":14671794,"price":0.012,"value":176061.528,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares whose sale is reported in this row are represented by American Depositary Shares (\"ADSs\") and are held of record by New Enterprise Associates 16, L.P. (\"NEA 16\"). NEA 16 holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.012 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0114 to $0.0130 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC (\"NEA 16 GP\"), which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-110254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025110254/ownership.xml","form_type":"4"}},{"id":1061204,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of 0.001 GBP per share","published_at":"2025-08-19T23:07:09.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":4828206,"price":0.011,"value":53110.266,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares whose sale is reported in this row are represented by American Depositary Shares (\"ADSs\") and are held of record by New Enterprise Associates 16, L.P. (\"NEA 16\"). NEA 16 holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.011 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0099 to $0.0118 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC (\"NEA 16 GP\"), which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":14671794,"source":{"system":"sec-edgar","filing":"0000950170-25-110254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025110254/ownership.xml","form_type":"4"}},{"id":1078949,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":48279,"kind":"organization","name":"EcoR1 Capital, LLC","position":1,"cik":"0001587114","reported_name":"EcoR1 Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-07-30T22:20:32.000Z","date":"2025-07-30","kind":"sale","planned":false,"acquired":false,"shares":27433338,"price":0.1021,"value":2800943.8098,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These Ordinary Shares are held through American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents 6 Ordinary Shares."},{"field":"shares","element":"transactionShares","label":"F9","text":"The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is the price per ADS sold by the reporting persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting persons are EcoR1 Capital, LLC (\"Ecor1\"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (\"Qualified Fund\"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the \"Fund\"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein."}],"balance_after":100371882,"source":{"system":"sec-edgar","filing":"0000935836-25-000476","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1587114/000093583625000476/ownership.xml","form_type":"4"}},{"id":1078948,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":48279,"kind":"organization","name":"EcoR1 Capital, LLC","position":1,"cik":"0001587114","reported_name":"EcoR1 Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-07-30T22:20:32.000Z","date":"2025-07-29","kind":"sale","planned":false,"acquired":false,"shares":2687460,"price":0.1012,"value":271970.952,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These Ordinary Shares are held through American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents 6 Ordinary Shares."},{"field":"shares","element":"transactionShares","label":"F6","text":"The reporting persons sold 447,910 ADSs representing 2,687,460 Ordinary Shares. Qualified Fund sold 418,303 of those ADSs, representing 2,509,818 Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is the price per ADS sold by the reporting persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"After this transaction, the reporting persons beneficially owned 21,300,870 ADSs, including 20,151,331 ADSs held by Qualified Fund representing 120,907,986 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting persons are EcoR1 Capital, LLC (\"Ecor1\"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (\"Qualified Fund\"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the \"Fund\"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein."}],"balance_after":127805220,"source":{"system":"sec-edgar","filing":"0000935836-25-000476","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1587114/000093583625000476/ownership.xml","form_type":"4"}},{"id":1078947,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":48279,"kind":"organization","name":"EcoR1 Capital, LLC","position":1,"cik":"0001587114","reported_name":"EcoR1 Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-07-30T22:20:32.000Z","date":"2025-07-28","kind":"sale","planned":false,"acquired":false,"shares":33931740,"price":0.1125,"value":3817320.75,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These Ordinary Shares are held through American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents 6 Ordinary Shares."},{"field":"shares","element":"transactionShares","label":"F3","text":"The reporting persons sold 5,655,290 ADSs representing 33,931,740 Ordinary Shares. Qualified Fund sold 5,281,476 of those ADSs, representing 31,688,856 Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the price per ADS sold by the reporting persons. This price is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.1086 to $0.1184, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"After this transaction, the reporting persons beneficially owned 21,748,780 ADSs, including 20,569,634 ADS held by Qualified Fund representing 123,417,804 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting persons are EcoR1 Capital, LLC (\"Ecor1\"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (\"Qualified Fund\"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the \"Fund\"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein."}],"balance_after":130492680,"source":{"system":"sec-edgar","filing":"0000935836-25-000476","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1587114/000093583625000476/ownership.xml","form_type":"4"}},{"id":1255409,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:35:34.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015746","document":"tm257186-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925015746/tm257186-6_4seq1.xml","form_type":"4"}},{"id":1255408,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:35:34.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015746","document":"tm257186-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925015746/tm257186-6_4seq1.xml","form_type":"4"}},{"id":1254998,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:33:25.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015743","document":"tm257186-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015743/tm257186-4_4seq1.xml","form_type":"4"}},{"id":1254997,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:33:25.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015743","document":"tm257186-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015743/tm257186-4_4seq1.xml","form_type":"4"}},{"id":1254990,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:32:35.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015742","document":"tm257186-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015742/tm257186-3_4seq1.xml","form_type":"4"}},{"id":1254989,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:32:35.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015742","document":"tm257186-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015742/tm257186-3_4seq1.xml","form_type":"4"}},{"id":1254988,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:31:45.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015741","document":"tm257186-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015741/tm257186-2_4seq1.xml","form_type":"4"}},{"id":1254987,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:31:45.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015741","document":"tm257186-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015741/tm257186-2_4seq1.xml","form_type":"4"}},{"id":1255156,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:30:23.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":3428832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":3428832,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":3428832},"source":{"system":"sec-edgar","filing":"0001104659-25-015739","document":"tm257186-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925015739/tm257186-1_4seq1.xml","form_type":"4"}},{"id":1255155,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:30:23.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":5143248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029."}],"balance_after":5143248,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":5143248},"source":{"system":"sec-edgar","filing":"0001104659-25-015739","document":"tm257186-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925015739/tm257186-1_4seq1.xml","form_type":"4"}},{"id":1256176,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82979,"kind":"person","name":"Brewer Joanna Elizabeth","position":1,"cik":"0001923834","reported_name":"Brewer Joanna Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T17:34:48.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015745","document":"tm257186-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923834/000110465925015745/tm257186-5_4seq1.xml","form_type":"4"}},{"id":1256175,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82979,"kind":"person","name":"Brewer Joanna Elizabeth","position":1,"cik":"0001923834","reported_name":"Brewer Joanna Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T17:34:48.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015745","document":"tm257186-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923834/000110465925015745/tm257186-5_4seq1.xml","form_type":"4"}},{"id":1299668,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-18T02:17:54.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":5584,"price":0.5808,"value":3243.1872,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 125,755 ADSs and RSU-style options and other options covering an aggregate of 8,772,230 ordinary shares of the Issuer."}],"balance_after":7510,"source":{"system":"sec-edgar","filing":"0001104659-25-004608","document":"tm253716-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925004608/tm253716-4_4seq1.xml","form_type":"4"}},{"id":1299667,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-18T02:17:14.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":5584,"price":0.5808,"value":3243.1872,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 163,380 ADSs and RSU-style options and other options covering an aggregate of 10,135,962 ordinary shares of the Issuer."}],"balance_after":7510,"source":{"system":"sec-edgar","filing":"0001104659-25-004607","document":"tm253716-3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925004607/tm253716-3_4.xml","form_type":"4"}},{"id":1299906,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-18T02:16:23.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":5584,"price":0.5808,"value":3243.1872,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 191,382 ADSs and RSU-style options and other options covering an aggregate of 13,421,994 ordinary shares of the Issuer."}],"balance_after":7510,"source":{"system":"sec-edgar","filing":"0001104659-25-004606","document":"tm253716-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925004606/tm253716-2_4seq1.xml","form_type":"4"}},{"id":1299704,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-18T02:15:20.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":30601,"price":0.5808,"value":17773.0608,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 350,900 ADSs and RSU-style options and other options covering an aggregate of 34,439,286 ordinary shares of the Issuer."}],"balance_after":44327,"source":{"system":"sec-edgar","filing":"0001104659-25-004605","document":"tm253716-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925004605/tm253716-1_4seq1.xml","form_type":"4"}},{"id":1302359,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:19:45.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":29096,"price":0.5748,"value":16724.3808,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer."}],"balance_after":41582,"source":{"system":"sec-edgar","filing":"0001104659-25-003775","document":"tm253441-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925003775/tm253441-5_4seq1.xml","form_type":"4"}},{"id":1302358,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:19:45.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":17934,"price":0.5879,"value":10543.3986,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer."}],"balance_after":25711,"source":{"system":"sec-edgar","filing":"0001104659-25-003775","document":"tm253441-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925003775/tm253441-5_4seq1.xml","form_type":"4"}},{"id":1302357,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:19:45.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":12539,"price":0.5879,"value":7371.6781,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer."}],"balance_after":17801,"source":{"system":"sec-edgar","filing":"0001104659-25-003775","document":"tm253441-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925003775/tm253441-5_4seq1.xml","form_type":"4"}},{"id":1302289,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:18:53.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":12991,"price":0.5748,"value":7467.2268,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 25% of the remaining balance of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 92,652 ADSs and RSU-style options and other options covering an aggregate of 6,779,928 ordinary shares of the Issuer."}],"balance_after":18421,"source":{"system":"sec-edgar","filing":"0001104659-25-003774","document":"tm253441-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003774/tm253441-4_4seq1.xml","form_type":"4"}},{"id":1302288,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:17:29.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":9803,"price":0.5748,"value":5634.7644,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 94,638 ADSs and RSU-style options and other options covering an aggregate of 8,850,794 ordinary shares of the Issuer."}],"balance_after":13756,"source":{"system":"sec-edgar","filing":"0001104659-25-003771","document":"tm253441-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003771/tm253441-3_4seq1.xml","form_type":"4"}},{"id":1302287,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:17:29.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":8124,"price":0.5879,"value":4776.0996,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 94,638 ADSs and RSU-style options and other options covering an aggregate of 8,850,794 ordinary shares of the Issuer."}],"balance_after":11516,"source":{"system":"sec-edgar","filing":"0001104659-25-003771","document":"tm253441-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003771/tm253441-3_4seq1.xml","form_type":"4"}},{"id":1302286,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:17:29.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":4268,"price":0.5879,"value":2509.1572,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 94,638 ADSs and RSU-style options and other options covering an aggregate of 8,850,794 ordinary shares of the Issuer."}],"balance_after":5845,"source":{"system":"sec-edgar","filing":"0001104659-25-003771","document":"tm253441-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003771/tm253441-3_4seq1.xml","form_type":"4"}},{"id":1302285,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:16:11.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":9803,"price":0.5748,"value":5634.7644,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 136,156 ADSs and RSU-style options and other options covering an aggregate of 10,214,526 ordinary shares of the Issuer."}],"balance_after":13756,"source":{"system":"sec-edgar","filing":"0001104659-25-003768","document":"tm253441-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003768/tm253441-2_4seq1.xml","form_type":"4"}},{"id":1302284,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:16:11.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":5471,"price":0.5879,"value":3216.4009,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 136,156 ADSs and RSU-style options and other options covering an aggregate of 10,214,526 ordinary shares of the Issuer."}],"balance_after":7623,"source":{"system":"sec-edgar","filing":"0001104659-25-003768","document":"tm253441-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003768/tm253441-2_4seq1.xml","form_type":"4"}},{"id":1302283,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:16:11.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":4268,"price":0.5879,"value":2509.1572,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 136,156 ADSs and RSU-style options and other options covering an aggregate of 10,214,526 ordinary shares of the Issuer."}],"balance_after":5845,"source":{"system":"sec-edgar","filing":"0001104659-25-003768","document":"tm253441-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003768/tm253441-2_4seq1.xml","form_type":"4"}},{"id":1302439,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:15:09.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":9803,"price":0.5748,"value":5634.7644,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer."}],"balance_after":13756,"source":{"system":"sec-edgar","filing":"0001104659-25-003765","document":"tm253441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925003765/tm253441-1_4seq1.xml","form_type":"4"}},{"id":1302438,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:15:09.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":5471,"price":0.5879,"value":3216.4009,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer."}],"balance_after":7623,"source":{"system":"sec-edgar","filing":"0001104659-25-003765","document":"tm253441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925003765/tm253441-1_4seq1.xml","form_type":"4"}},{"id":1302437,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:15:09.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":4268,"price":0.5879,"value":2509.1572,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer."}],"balance_after":5845,"source":{"system":"sec-edgar","filing":"0001104659-25-003765","document":"tm253441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925003765/tm253441-1_4seq1.xml","form_type":"4"}},{"id":1465483,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:10:03.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1144686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of U.S.$1.263714 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":1144686,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1144686},"source":{"system":"sec-edgar","filing":"0000950170-24-079752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017024079752/ownership.xml","form_type":"4"}},{"id":1465589,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:04:22.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1583214,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1583214,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1583214},"source":{"system":"sec-edgar","filing":"0001104659-24-076897","document":"tm2418639-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000110465924076897/tm2418639-7_4seq1.xml","form_type":"4"}},{"id":1465509,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:03:53.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1121604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1121604,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1121604},"source":{"system":"sec-edgar","filing":"0001104659-24-076895","document":"tm2418639-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465924076895/tm2418639-6_4seq1.xml","form_type":"4"}},{"id":1465818,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":37690,"kind":"person","name":"Furey John","position":1,"cik":"0001691218","reported_name":"Furey John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:02:06.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":660000,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001104659-24-076891","document":"tm2418639-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691218/000110465924076891/tm2418639-3_4seq1.xml","form_type":"4"}},{"id":1465508,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":26161,"kind":"person","name":"Alleva Lawrence M","position":1,"cik":"0001553053","reported_name":"Alleva Lawrence M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:01:32.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1213926,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1213926,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1213926},"source":{"system":"sec-edgar","filing":"0001104659-24-076890","document":"tm2418639d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553053/000110465924076890/tm2418639d2_4seq1.xml","form_type":"4"}},{"id":1465544,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:00:32.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":660000,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001104659-24-076887","document":"tm2418639-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465924076887/tm2418639-1_4seq1.xml","form_type":"4"}},{"id":1465672,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T17:03:24.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of U.S.$ 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":660000,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001104659-24-076894","document":"tm2418639-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1299171/000110465924076894/tm2418639-5_4seq1.xml","form_type":"4"}},{"id":1466039,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":89357,"kind":"person","name":"Hegde Priti","position":1,"cik":"0001880034","reported_name":"Hegde Priti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T17:02:51.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1144686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1144686,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1144686},"source":{"system":"sec-edgar","filing":"0001104659-24-076893","document":"tm2418639-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880034/000110465924076893/tm2418639-4_4seq1.xml","form_type":"4"}},{"id":1474580,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-18T21:00:13.000Z","date":"2024-06-18","kind":"sale","planned":false,"acquired":false,"shares":24531,"price":0.93,"value":22813.83,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately one third of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,359 ADSs and RSU-style options and other options covering an aggregate of 6,968,400 ordinary shares of the Issuer."}],"balance_after":38293,"source":{"system":"sec-edgar","filing":"0001104659-24-072874","document":"tm2417532-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924072874/tm2417532-1_4seq1.xml","form_type":"4"}},{"id":1571905,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-03-18T21:00:12.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":1130832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 376,944 Ordinary Shares on June 18, 2024 and will be exercisable as to the remainder in installments of 188,472 Ordinary Shares on January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1130832,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1130832},"source":{"system":"sec-edgar","filing":"0001104659-24-035619","document":"tm249079d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924035619/tm249079d1_4seq1.xml","form_type":"4"}},{"id":1571904,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-03-18T21:00:12.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":5088864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.19 based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,679,325 Ordinary Shares on March 18, 2024 and will be exercisable as to the remainder in monthly installments of 94,704 Ordinary Shares on the last day of each month from April 18, 2024 through February 18, 2027 and 94,899 Ordinary Shares on March 18, 2027."}],"balance_after":5088864,"derivative":{"exercise_price":0.25,"expiration_date":"2034-03-18","underlying":"Ordinary Shares","underlying_shares":5088864},"source":{"system":"sec-edgar","filing":"0001104659-24-035619","document":"tm249079d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924035619/tm249079d1_4seq1.xml","form_type":"4"}},{"id":1677572,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:52.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":30080,"price":0.673,"value":20243.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer."}],"balance_after":44848,"source":{"system":"sec-edgar","filing":"0001104659-24-004564","document":"tm243270-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004564/tm243270-16_4seq1.xml","form_type":"4"}},{"id":1677571,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:52.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":9304,"price":0.79,"value":7350.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer."}],"balance_after":14104,"source":{"system":"sec-edgar","filing":"0001104659-24-004564","document":"tm243270-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004564/tm243270-16_4seq1.xml","form_type":"4"}},{"id":1677535,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:27.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":12967,"price":0.673,"value":8726.791,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,233 ADSs and RSU-style options and other options covering an aggregate of 9,170,666 ordinary shares of the Issuer"}],"balance_after":19257,"source":{"system":"sec-edgar","filing":"0001104659-24-004563","document":"tm243270-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004563/tm243270-15_4seq1.xml","form_type":"4"}},{"id":1677534,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:27.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":5309,"price":0.673,"value":3572.957,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,233 ADSs and RSU-style options and other options covering an aggregate of 9,170,666 ordinary shares of the Issuer."}],"balance_after":7785,"source":{"system":"sec-edgar","filing":"0001104659-24-004563","document":"tm243270-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004563/tm243270-15_4seq1.xml","form_type":"4"}},{"id":1677533,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:27.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":2287,"price":0.79,"value":1806.73,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,233 ADSs and RSU-style options and other options covering an aggregate of 9,170,666 ordinary shares of the Issuer."}],"balance_after":3363,"source":{"system":"sec-edgar","filing":"0001104659-24-004563","document":"tm243270-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004563/tm243270-15_4seq1.xml","form_type":"4"}},{"id":1677532,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:50.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":12805,"price":0.673,"value":8617.765,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in his Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer."}],"balance_after":19015,"source":{"system":"sec-edgar","filing":"0001104659-24-004562","document":"tm243270-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004562/tm243270-14_4seq1.xml","form_type":"4"}},{"id":1677531,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:50.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":5309,"price":0.673,"value":3572.957,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer."}],"balance_after":7785,"source":{"system":"sec-edgar","filing":"0001104659-24-004562","document":"tm243270-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004562/tm243270-14_4seq1.xml","form_type":"4"}},{"id":1677530,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:50.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":4681,"price":0.79,"value":3697.99,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer."}],"balance_after":7023,"source":{"system":"sec-edgar","filing":"0001104659-24-004562","document":"tm243270-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004562/tm243270-14_4seq1.xml","form_type":"4"}},{"id":1677683,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:20.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":13599,"price":0.673,"value":9152.127,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer."}],"balance_after":20201,"source":{"system":"sec-edgar","filing":"0001104659-24-004560","document":"tm243270-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004560/tm243270-13_4seq1.xml","form_type":"4"}},{"id":1677682,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:20.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":5309,"price":0.673,"value":3572.957,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer."}],"balance_after":7785,"source":{"system":"sec-edgar","filing":"0001104659-24-004560","document":"tm243270-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004560/tm243270-13_4seq1.xml","form_type":"4"}},{"id":1677681,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:20.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":4681,"price":0.79,"value":3697.99,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer."}],"balance_after":7023,"source":{"system":"sec-edgar","filing":"0001104659-24-004560","document":"tm243270-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004560/tm243270-13_4seq1.xml","form_type":"4"}},{"id":1677539,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:06:47.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":40950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":40950,"derivative":{"exercise_price":0.14,"exercise_date":"2025-01-15","expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":40950},"source":{"system":"sec-edgar","filing":"0001209191-24-001773","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000120919124001773/doc4.xml","form_type":"4"}},{"id":1677680,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:03:43.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004531","document":"tm243270-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004531/tm243270-12_4seq1.xml","form_type":"4"}},{"id":1677679,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:03:43.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004531","document":"tm243270-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004531/tm243270-12_4seq1.xml","form_type":"4"}},{"id":1677529,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:02:36.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004528","document":"tm243270-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004528/tm243270-10_4seq1.xml","form_type":"4"}},{"id":1677528,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:02:36.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004528","document":"tm243270-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004528/tm243270-10_4seq1.xml","form_type":"4"}},{"id":1677527,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:01:40.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004525","document":"tm243270-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004525/tm243270-8_4seq1.xml","form_type":"4"}},{"id":1677526,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":54977,"kind":"person","name":"TAYTON-MARTIN HELEN KATRINA","position":1,"cik":"0001661780","reported_name":"TAYTON-MARTIN HELEN KATRINA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Strgy Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:01:40.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004525","document":"tm243270-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004525/tm243270-8_4seq1.xml","form_type":"4"}},{"id":1677525,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:01:00.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004523","document":"tm243270-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004523/tm243270-6_4seq1.xml","form_type":"4"}},{"id":1677524,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:01:00.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004523","document":"tm243270-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924004523/tm243270-6_4seq1.xml","form_type":"4"}},{"id":1677570,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:00:22.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":1696272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 424,068 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 424,068 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1696272,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1696272},"source":{"system":"sec-edgar","filing":"0001104659-24-004520","document":"tm243270-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004520/tm243270-5_4seq1.xml","form_type":"4"}},{"id":1677569,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:00:22.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":7633296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,908,324 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 159,024 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 159,132 Ordinary Shares on January 15, 2028."}],"balance_after":7633296,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":7633296},"source":{"system":"sec-edgar","filing":"0001104659-24-004520","document":"tm243270-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004520/tm243270-5_4seq1.xml","form_type":"4"}},{"id":1677689,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:03:04.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":81906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":81906,"derivative":{"exercise_price":0.14,"exercise_date":"2025-01-15","expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":81906},"source":{"system":"sec-edgar","filing":"0001104659-24-004530","document":"tm243270-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1299171/000110465924004530/tm243270-11_4seq1.xml","form_type":"4"}},{"id":1678131,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82979,"kind":"person","name":"Brewer Joanna Elizabeth","position":1,"cik":"0001923834","reported_name":"Brewer Joanna Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:02:11.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004527","document":"tm243270-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923834/000110465924004527/tm243270-9_4seq1.xml","form_type":"4"}},{"id":1678130,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82979,"kind":"person","name":"Brewer Joanna Elizabeth","position":1,"cik":"0001923834","reported_name":"Brewer Joanna Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:02:11.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004527","document":"tm243270-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923834/000110465924004527/tm243270-9_4seq1.xml","form_type":"4"}},{"id":1677555,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:01:14.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004524","document":"tm243270-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465924004524/tm243270-7_4seq1.xml","form_type":"4"}},{"id":1677554,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:01:14.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004524","document":"tm243270-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465924004524/tm243270-7_4seq1.xml","form_type":"4"}},{"id":1679756,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:46.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":7799,"price":0.8541,"value":6661.1259,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 46,288 ADSs and RSU-style options and other options covering an aggregate of 6,366,626 ordinary shares of the Issuer."}],"balance_after":11841,"source":{"system":"sec-edgar","filing":"0001104659-24-003743","document":"tm243270-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924003743/tm243270-2_4seq1.xml","form_type":"4"}},{"id":1679755,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82961,"kind":"person","name":"Norry Elliot","position":1,"cik":"0001798117","reported_name":"Norry Elliot","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:46.000Z","date":"2024-01-11","kind":"sale","planned":false,"acquired":false,"shares":4009,"price":0.8367,"value":3354.3303,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 46,288 ADSs and RSU-style options and other options covering an aggregate of 6,366,626 ordinary shares of the Issuer."}],"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001104659-24-003743","document":"tm243270-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924003743/tm243270-2_4seq1.xml","form_type":"4"}},{"id":1679902,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:44.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":5220,"price":0.8541,"value":4458.402,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer."}],"balance_after":7874,"source":{"system":"sec-edgar","filing":"0001104659-24-003745","document":"tm243270-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924003745/tm243270-4_4seq1.xml","form_type":"4"}},{"id":1679901,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:44.000Z","date":"2024-01-11","kind":"sale","planned":false,"acquired":false,"shares":4009,"price":0.8367,"value":3354.3303,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer."}],"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001104659-24-003745","document":"tm243270-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924003745/tm243270-4_4seq1.xml","form_type":"4"}},{"id":1679788,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:41.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":17257,"price":0.8541,"value":14739.2037,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 162,071 ADSs and RSU-style options and other options covering an aggregate of 27,017,280 ordinary shares of the Issuer."}],"balance_after":26388,"source":{"system":"sec-edgar","filing":"0001104659-24-003742","document":"tm243270-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924003742/tm243270-1_4seq1.xml","form_type":"4"}},{"id":1679787,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:41.000Z","date":"2024-01-11","kind":"sale","planned":false,"acquired":false,"shares":11945,"price":0.8367,"value":9994.3815,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 162,071 ADSs and RSU-style options and other options covering an aggregate of 27,017,280 ordinary shares of the Issuer."}],"balance_after":18395,"source":{"system":"sec-edgar","filing":"0001104659-24-003742","document":"tm243270-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924003742/tm243270-1_4seq1.xml","form_type":"4"}},{"id":1679754,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:37.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":5220,"price":0.8541,"value":4458.402,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 88,355 ADSs and RSU-style options and other options covering an aggregate of 7,724,982 ordinary shares of the Issuer."}],"balance_after":7874,"source":{"system":"sec-edgar","filing":"0001104659-24-003744","document":"tm243270-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924003744/tm243270-3_4seq1.xml","form_type":"4"}},{"id":1679753,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:37.000Z","date":"2024-01-11","kind":"sale","planned":false,"acquired":false,"shares":4009,"price":0.8367,"value":3354.3303,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 88,355 ADSs and RSU-style options and other options covering an aggregate of 7,724,982 ordinary shares of the Issuer."}],"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001104659-24-003744","document":"tm243270-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924003744/tm243270-3_4seq1.xml","form_type":"4"}},{"id":1790611,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-09-01T23:00:26.000Z","date":"2023-09-01","kind":"sale","planned":false,"acquired":false,"shares":2403,"price":0.78,"value":1874.34,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 158,622 ADSs and RSU-style options and other options covering an aggregate of 27,461,190 ordinary shares of the Issuer."}],"balance_after":3449,"source":{"system":"sec-edgar","filing":"0001104659-23-097853","document":"tm2325388-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923097853/tm2325388-1_4seq1.xml","form_type":"4"}},{"id":1818931,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":82962,"kind":"person","name":"Lunger John","position":1,"cik":"0001784487","reported_name":"Lunger John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Supply Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-08-01T21:00:14.000Z","date":"2023-08-01","kind":"sale","planned":false,"acquired":false,"shares":3096,"price":0.9056,"value":2803.7376,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 83,637 ADSs and RSU-style options and other options covering an aggregate of 7,864,224 ordinary shares of the Issuer."}],"balance_after":4718,"source":{"system":"sec-edgar","filing":"0001104659-23-086416","document":"tm2320966-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923086416/tm2320966-2_4seq1.xml","form_type":"4"}},{"id":1832070,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-07-10T21:01:03.000Z","date":"2023-07-10","kind":"sale","planned":false,"acquired":false,"shares":47702,"price":0.9108,"value":43446.9816,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on July 5, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.9100 to $0.9211, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 611,224 ADSs and share options covering an aggregate of 11,093,593 ordinary shares of the Issuer. Included in the 611,224 ADSs are 200,646 ADSs held by the Garry E. Menzel Revocable Trust of 2022 (the \"Menzel Trust\") and 200,647 ADSs held by the Mary E. Henshall Revocable Trust of 2022 (the \"Henshall Trust\"). The Reporting Person is the trustee of the Menzel Trust and the Reporting Person's spouse is the trustee of the Henshall Trust and, as such, the Reporting Person may be deemed to beneficially own these securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust and the Henshall Trust."}],"balance_after":75056,"source":{"system":"sec-edgar","filing":"0001104659-23-079700","document":"tm2320966-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923079700/tm2320966-1_4seq1.xml","form_type":"4"}},{"id":1835382,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:03:13.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":152376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Will be exercisable as to 38,094 Ordinary Shares on December 15, 2023 and will be exercisable as to the remainder in monthly installments of 4,758 Ordinary Shares on the fifteenth of each month from January 15, 2024 through November 15, 2025 and 4,848 Ordinary Shares on December 15, 2025."}],"balance_after":152376,"derivative":{"exercise_price":0.11,"expiration_date":"2032-12-14","underlying":"Ordinary Shares","underlying_shares":152376},"source":{"system":"sec-edgar","filing":"0001104659-23-078197","document":"tm2320409-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465923078197/tm2320409-9_4seq1.xml","form_type":"4"}},{"id":1835381,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:03:13.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":109746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Currently exercisable as to 48,006 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 3,430 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2025."}],"balance_after":109746,"derivative":{"exercise_price":0.57,"expiration_date":"2031-12-08","underlying":"Ordinary Shares","underlying_shares":109746},"source":{"system":"sec-edgar","filing":"0001104659-23-078197","document":"tm2320409-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465923078197/tm2320409-9_4seq1.xml","form_type":"4"}},{"id":1835380,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:03:13.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":109746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price was converted from GBP2.76, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable as to 68,586 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 2,286 Ordinary Shares on the first of each month from August 1, 2023 through December 1, 2024 and 2,298 Ordinary Shares on January 1, 2025."}],"balance_after":109746,"derivative":{"exercise_price":3.51,"expiration_date":"2030-12-09","underlying":"Ordinary Shares","underlying_shares":109746},"source":{"system":"sec-edgar","filing":"0001104659-23-078197","document":"tm2320409-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465923078197/tm2320409-9_4seq1.xml","form_type":"4"}},{"id":1835379,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:03:13.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":45348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price was converted from GBP1.40, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Currently exercisable as to 39,684 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 944 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2024."}],"balance_after":45348,"derivative":{"exercise_price":1.78,"expiration_date":"2029-12-18","underlying":"Ordinary Shares","underlying_shares":45348},"source":{"system":"sec-edgar","filing":"0001104659-23-078197","document":"tm2320409-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465923078197/tm2320409-9_4seq1.xml","form_type":"4"}},{"id":1835378,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:03:13.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":56868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price was converted from GBP1.40, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":56868,"derivative":{"exercise_price":1.78,"expiration_date":"2029-04-10","underlying":"Ordinary Shares","underlying_shares":56868},"source":{"system":"sec-edgar","filing":"0001104659-23-078197","document":"tm2320409-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465923078197/tm2320409-9_4seq1.xml","form_type":"4"}},{"id":1835377,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36722,"kind":"person","name":"Allen Andrew R","position":1,"cik":"0001374539","reported_name":"Allen Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:03:13.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":73212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.70, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":73212,"derivative":{"exercise_price":0.89,"expiration_date":"2028-12-12","underlying":"Ordinary Shares","underlying_shares":73212},"source":{"system":"sec-edgar","filing":"0001104659-23-078197","document":"tm2320409-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374539/000110465923078197/tm2320409-9_4seq1.xml","form_type":"4"}},{"id":1835257,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":2158776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":2158776,"derivative":{"exercise_price":0.11,"expiration_date":"2032-12-14","underlying":"Ordinary Shares","underlying_shares":2158776},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835256,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":2715816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":2715816,"derivative":{"exercise_price":0.57,"expiration_date":"2031-12-08","underlying":"Ordinary Shares","underlying_shares":2715816},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835255,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":57846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":57846,"derivative":{"exercise_price":0.57,"expiration_date":"2031-12-08","underlying":"Ordinary Shares","underlying_shares":57846},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835254,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":3568026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price was converted from GBP0.51, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":3568026,"derivative":{"exercise_price":0.65,"expiration_date":"2028-07-25","underlying":"Ordinary Shares","underlying_shares":3568026},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835253,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":359700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price was converted from GBP0.51, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":359700,"derivative":{"exercise_price":0.65,"expiration_date":"2028-07-25","underlying":"Ordinary Shares","underlying_shares":359700},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835252,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":1251966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price was converted from GBP0.07, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":1251966,"derivative":{"exercise_price":0.08,"expiration_date":"2027-12-07","underlying":"Ordinary Shares","underlying_shares":1251966},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835251,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":736548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding restricted stock units with respect to TCRR common stock (each, a \"TCRR RSU\") were assumed by the Issuer and substituted for a restricted stock unit-style option to purchase Ordinary Shares (each, an \"Adjusted Restricted Stock Unit Equivalent\"), with an exercise price equal to GBP0.001, the nominal value of an Ordinary Share and on substantially similar terms and conditions as were applicable to such TCRR RSUs."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Restricted Stock Unit Equivalent is equal to (A) the ADS Exchange Ratio multiplied by six (such product, the \"Ordinary Share Exchange Ratio\") multiplied by (B) the total number of shares of TCRR common stock subject to such TCRR RSU. Each Adjusted Restricted Stock Unit Equivalent was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":736548,"derivative":{"exercise_price":0.0013,"expiration_date":"2024-03-15","underlying":"Ordinary Shares","underlying_shares":736548},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1836830,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":89357,"kind":"person","name":"Hegde Priti","position":1,"cik":"0001880034","reported_name":"Hegde Priti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T17:05:16.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":152376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Will be exercisable as to 38,094 Ordinary Shares on December 15, 2023 and will be exercisable as to the remainder in monthly installments of 4,758 Ordinary Shares on the fifteenth of each month from January 15, 2024 through November 15, 2025 and 4,848 Ordinary Shares on December 15, 2025."}],"balance_after":152376,"derivative":{"exercise_price":0.11,"expiration_date":"2032-12-14","underlying":"Ordinary Shares","underlying_shares":152376},"source":{"system":"sec-edgar","filing":"0001104659-23-078201","document":"tm2320409-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880034/000110465923078201/tm2320409-10_4seq1.xml","form_type":"4"}},{"id":1836829,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":89357,"kind":"person","name":"Hegde Priti","position":1,"cik":"0001880034","reported_name":"Hegde Priti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T17:05:16.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":109746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an \"Ordinary Share\") (each such option, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the \"Ordinary Share Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Currently exercisable as to 48,006 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 3,430 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2025."}],"balance_after":109746,"derivative":{"exercise_price":0.57,"expiration_date":"2031-12-08","underlying":"Ordinary Shares","underlying_shares":109746},"source":{"system":"sec-edgar","filing":"0001104659-23-078201","document":"tm2320409-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880034/000110465923078201/tm2320409-10_4seq1.xml","form_type":"4"}}],"next_cursor":"2023-07-05T17:05:16.000000Z,1836829"}